- Home
- WDS vs TEVA Comparison
WDS vs TEVA Comparison
Compare WDS & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WDS | TEVA |
|---|---|---|
| Founded | 1954 | 1901 |
| Country | Australia | Israel |
| Employees | 4667 | 32842 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.3B | 39.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WDS | TEVA |
|---|---|---|
| Price | $20.11 | $33.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $38.63 |
| AVG Volume (30 Days) | 1.2M | ★ 5.3M |
| Earning Date | 02-23-2026 | 04-29-2026 |
| Dividend Yield | ★ 4.50% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.14 | N/A |
| Revenue Next Year | $4.92 | $2.97 |
| P/E Ratio | ★ $11.81 | $28.19 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.27 | $14.99 |
| 52 Week High | $25.19 | $37.35 |
Technical Indicators
Market Signals| Indicator | WDS | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 46.25 | 46.69 |
| Support Level | $18.80 | $30.59 |
| Resistance Level | $24.91 | $35.33 |
| Average True Range (ATR) | 0.27 | 1.08 |
| MACD | 0.16 | -0.01 |
| Stochastic Oscillator | 79.38 | 45.23 |
Price Performance
Historical ComparisonAbout WDS Woodside Energy Group Limited
Incorporated in 1954 and named after the small Victorian town of Woodside, Woodside's early exploration focus moved from Victoria's Gippsland Basin to Western Australia's Carnarvon Basin. First LNG production from the North West Shelf came in 1984. BHP Billiton and Shell each had 40% shareholdings before BHP sold out in 1994 and Shell sold down to 34%. In 2017 Shell sold its entire shareholding. Woodside is one of the most LNG-leveraged companies globally.
About TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.